Wockhardt Limited reported a strong revenue performance for the second quarter of FY27, with revenue rising 24% year-on-year to Rs 969 crore, compared with Rs 782 crore in the corresponding quarter last year.

 

For the first half of FY27, the pharmaceutical company posted a 25% jump in revenue to Rs 1,898 crore, up from Rs 1,520 crore in the year-ago period.

 

EBITDA for Q2 FY27 stood at Rs 165 crore, marginally higher than Rs 160 crore in Q2 FY26. However, excluding pre-Zaynich launch expenses, EBITDA rose to Rs 201 crore.

 

The company's first-half operating performance was stronger, with EBITDA climbing 35% to Rs 353 crore against Rs 261 crore in H1 FY26. Excluding pre-Zaynich launch expenses, H1 EBITDA stood at Rs 398 crore.

 

EBITDA margins for the first half improved to 18.6%, compared with 17.2% in the corresponding period last year. On an adjusted basis, excluding pre-Zaynich launch expenses, margins stood at 21%.

 

Profit after tax for Q2 FY27 came in at Rs 73 crore, compared with Rs 82 crore in the same quarter last year. For H1 FY27, PAT stood at Rs 180 crore, against a loss of Rs 26 crore in the year-ago period.

 

Profit before tax for the first half reached Rs 189 crore, compared with a loss of Rs 18 crore in H1 FY26.

 

Wockhardt's biotech operations delivered a standout performance, recording revenue of Rs 252 crore in Q2 FY27, a sharp 68% increase over the corresponding quarter last year.

 

For the first half, biotech revenue surged 87% to Rs 487 crore.

 

The company attributed the strong momentum to its emerging-market biotech business, which grew approximately 110% in H1 FY27, supported by accelerated business opportunities and strategic partnerships.

 

New business wins and partnerships across key markets, including Brazil, Thailand, Egypt, Algeria and Latin America, further strengthened the company's growth trajectory.

 

Wockhardt said its India biotech operations also continued to expand at a double-digit pace, positioning the business for further growth.

 

The company highlighted its integrated biotechnology infrastructure as a key competitive strength, underlining its ability to support expansion across markets.

 

Reaffirming its focus on the diabetes segment, Wockhardt said it remained committed to addressing global diabetes healthcare needs and advancing its leadership in diabetes care.

 

With revenue growth of 25% in H1 FY27, a 35% rise in EBITDA and an 87% surge in biotech operations, Wockhardt has delivered a strong first-half performance, with its biotech business emerging as a key growth engine.